| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.aurolabs.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 112.00 Cr. | |
| Earnings per share (EPS) | 11.52 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 15.60 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.25 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 45.86 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 3.92 | Calculated using Price: 179.70 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.62 Cr. | 6,232,500 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah. Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum. Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others. Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management. Products APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more. Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid. Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and 5-Bromo Phthalide Milestones 1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim. 1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE). 2004-Company received ISO 9001:2000 certification. 2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM). 2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride. Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market. |
||
Company Profile
Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.
Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.
Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others. Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.
Products
APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.
Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.
Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and 5-Bromo Phthalide
Milestones
1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.
1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).
2004-Company received ISO 9001:2000 certification.
2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).
2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.
Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.
| 1 Day |
|
+3.93% |
| 1 Week |
|
+3.45% |
| 1 Month |
|
+43.93% |
| 3 Month |
|
+74.04% |
| 6 Month |
|
+87.29% |
| 1 Year |
|
+325.33% |
| 2 Year |
|
+215.82% |
| 5 Year |
|
+558.24% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 4.83 | 12.91 | 8.76 | 11.01 | 10.83 | 9.06 | 31.53 | 28.95 | 20.84 | |
| Return on Capital Employed (%) | 8.47 | 11.76 | 9.40 | 10.76 | 11.21 | 20.24 | 28.65 | 29.12 | 24.80 | |
| Return on Assets (%) | 1.07 | 2.71 | 2.04 | 2.89 | 3.24 | 3.11 | 12.34 | 13.78 | 12.32 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 6 | 6 | 7 | 8 | 9 | 9 | 13 | 17 | 22 | |
| Non Curr. Liab. | 9 | 8 | 7 | 8 | 7 | 11 | 8 | 6 | 5 | |
| Curr. Liab. | 12 | 15 | 13 | 14 | 10 | 6 | 10 | 10 | 6 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 27 | 30 | 27 | 29 | 26 | 27 | 30 | 33 | 32 | |
| Non Curr. Assets | 11 | 11 | 11 | 11 | 13 | 13 | 15 | 15 | 14 | |
| Curr. Assets | 16 | 19 | 16 | 18 | 12 | 14 | 16 | 19 | 18 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 27 | 30 | 27 | 29 | 26 | 27 | 30 | 33 | 32 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 25 | 44 | 34 | 33 | 28 | 35 | 41 | 47 | 44 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |
| Total Income | 25 | 44 | 34 | 33 | 28 | 36 | 41 | 48 | 45 | |
| Total Expenditure | -23 | -41 | -31 | -30 | -25 | -31 | -34 | -40 | -38 | |
| PBIDT | 2 | 3 | 3 | 3 | 3 | 5 | 7 | 8 | 7 | |
| Interest | -1 | -2 | -2 | -2 | -2 | -1 | -1 | -1 | -1 | |
| Depreciation | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -2 | -1 | -2 | -2 | ||||||
| Exceptional Items | ||||||||||
| PAT | 0 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 4 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | 1 | 4 | -1 | 8 | 6 | 5 | 7 | 9 | |
| Cash Fr. Inv. | -4 | -1 | -1 | -1 | -2 | -2 | -2 | -3 | -2 | |
| Cash Fr. Finan. | 1 | -1 | -3 | 1 | -5 | -4 | -2 | -2 | -5 | |
| Net Change | 0 | 0 | 1 | -1 | 0 | 0 | 1 | 2 | 2 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 4 | 6 |
|
Sat, 24 Jul 2021
Board Meeting Intimation for Board Meeting Intimation For Approval Of Financial Results For The Quarter Ended June 30 2021 AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2021 inter alia to consider and approve AURO LABORATORIES LIMITED has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on Thursday August 5 2021 inter alia to consider and approve the Un-Audited Financial Results for the quarter ended June 30 2021 and any other matters with the permission of the Chair. |
|
Sat, 17 Jul 2021
Shareholding for the Period Ended June 30 2021 Auro Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
|
Thu, 15 Jul 2021
Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI Listing Regulations 2015 Pursuant Regulation 23(9) of SEBI (LODR) Regulations 2015 we are enclosing herewith disclosure of Related Party Transactions on consolidated basis in accordance with the applicable accounting standards for the half year ended March 31 2021. |
| Mon, 26 Jul 2021 |
Stock Outperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Outperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Outperforming Benchmark Index
|
Strongly Outperforming Sectoral Index
|
Increasing Relative Strength - Sectoral Index
|
Equities
M.F.
Sectors